HCYTA-60K
MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A - Immunology Multiplex Assay
Synonym(s):
Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12161503
NACRES:
NA.84
Recommended Products
species reactivity
human
Quality Level
manufacturer/tradename
Milliplex®
technique(s)
multiplexing: suitable
input
cell culture supernatant(s)
plasma
serum
detection method
fluorometric (Luminex® xMAP®)
shipped in
wet ice
storage temp.
2-8°C
General description
Cytokines, chemokines, and growth factors are key mediatorsof immune system functions capable of signaling through autocrine, paracrine,and endocrine mechanisms. Their pleiotropic immunomodulatory propertiesallow these biomolecules to react to diverse stimuli and regulate the immuneresponse, either promoting or inhibiting inflammation.
Application
- MILLIPLEX® Qualified assays undergo rigorousassay development, verification, and Quality Control testing to achieve optimalperformance.
- Simultaneously analyze up to 48 cytokine,chemokine, and growth factor biomarkers with bead-based multiplex assays usingLuminex technology, in human serum, plasma and cell culture samples.
- Available analytes: sCD40L, EGF, Eotaxin, FGF-2,FLT-3L, Fractalkine, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA,IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10,MCP-1, MCP-3, M-CSF, MDC, MIG, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES,TGFα, TNFα, TNFβ, VEGF-A
Features and Benefits
- This panel is fully configurable, with options for custom bead premixing, fixed premixed and bulk premixed panels.
- Save time and resources by simultaneously analyzing up to 48 analytes of your choice in a single sample
- Requires a small sample volume (25 µL/well)
- Choose same day or overnight incubation
- Reliable and accurate performance with proven lot-to-lot consistency
- Ready-to-use reagents
- Comes with everything you need to run your assay
- Includes a Serum Matrix to mimic the native sample environment in serum and plasma samples
- Includes high and low Quality Controls
Packaging
96-well plate
Storage and Stability
Recommended storage for kit components is 2 - 8°C.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
Unless otherwise stated in our catalogor other company documentation accompanying the product(s), our products areintended for research use only and are not to be used for any other purpose,which includes but is not limited to, unauthorized commercial uses, in vitrodiagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumptionor application to humans or animals.
recommended
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
Target Organs
Respiratory Tract
Storage Class Code
10 - Combustible liquids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Teslin S Sandstrom et al.
Journal of virology, 95(9) (2021-02-12)
The use of unique cell surface markers to target and eradicate HIV-infected cells has been a longstanding objective of HIV-1 cure research. This approach, however, overlooks the possibility that intracellular changes present within HIV-infected cells may serve as valuable therapeutic
Myung-Ho Kim et al.
The Journal of infectious diseases (2021-05-27)
We analyzed the plasma levels of interferons and cytokines, and the expression of interferon-stimulated genes in peripheral blood mononuclear cells in COVID-19 patients with different disease severity. Mild patients exhibited transient type I interferon responses, while ICU patients had prolonged
Kelsey E Huntington et al.
eLife, 10 (2021-01-15)
Although the range of immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is variable, cytokine storm is observed in a subset of symptomatic individuals. To further understand the disease pathogenesis and, consequently, to develop an additional tool for
Jinyu Li et al.
Frontiers in immunology, 12, 749618-749618 (2021-12-11)
Increasing cases related to the pathogenicity of Enterovirus D68 (EV-D68) have made it a growing worldwide public health concern, especially due to increased severe respiratory illness and acute flaccid myelitis (AFM) in children. There are currently no vaccines or medicines
Andrea R Daamen et al.
Frontiers in immunology, 13, 989556-989556 (2022-10-04)
COVID-19 manifests a spectrum of respiratory symptoms, with the more severe often requiring hospitalization. To identify markers for disease progression, we analyzed longitudinal gene expression data from patients with confirmed SARS-CoV-2 infection admitted to the intensive care unit (ICU) for
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service